Intravitreal daptomycin: A safety and efficacy study

Retina

Volumn 31, Issue 6, 2011, Pages 1199-1206

  Comer, Grant M ^a   Miller, John B ^a   Schneider, Eric W ^a   Khan, Naheed W ^a   Reed, David M ^a   Elner, Victor M ^a   Zacks, David N ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

antibiotic resistance; Daptomycin; endophthalmitis

Indexed keywords

ATROPINE; DAPTOMYCIN; PHENYLEPHRINE; PROXYMETACAINE; TROPICAMIDE; XYLAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATARACT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ELECTRORETINOGRAPHY; ENDOPHTHALMITIS; EYE INFECTION; MALE; NONHUMAN; STAPHYLOCOCCUS EPIDERMIDIS;

ANIMALS; ANTI-BACTERIAL AGENTS; CATARACT; DAPTOMYCIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRORETINOGRAPHY; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; INTRAVITREAL INJECTIONS; MALE; RABBITS; RETINA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE;

EID: 79958255836     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318207d1b9     Document Type: Article

References (50)

1. Goulding MR, Rogers ME, Smith SM. Public health and aging: trends in aging\United States and worldwide. MMWR Morb Mortal Wkly Rep 2003;52:101-106.
2. McCarty CA, Keeffe JE, Taylor HR. The need for cataract surgery: projections based on lens opacity, visual acuity, and personal concern. Br J Ophthalmol 1999;83:62-65. (Pubitemid 29106333)
3. Leaming DV. Practice styles and preferences of ASCRS members\2003 survey. J Cataract Refract Surg 2004;30:892-900. (Pubitemid 38501487)
4. West ES, Behrens A, McDonnell PJ, Tielsch JM, Schein OD. The incidence of endophthalmitis after cataract surgery among the US Medicare population increased between 1994 and 2001. Ophthalmology 2005;112:1388-1394. (Pubitemid 41074627)
5. Taban M, Behrens A, Newcomb RL, et al. Acute endoph-thalmitis following cataract surgery. Arch Ophthalmol 2005; 123:613-620.
6. Kunimoto DY, Kaiser RS, Wills Eye Retina Service. Incidence of endophthalmitis after 20-and 25-gauge vitrectomy. Ophthalmology 2007;114:2133-2137. (Pubitemid 350181132)
7. Endophthalmitis Vitrectomy Study Group. Microbiologic factors and visual outcome in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996;122:830-846.
8. Endophthalmitis Vitrectomy Study Group. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmi-tis Vitrectomy Study. Am J Ophthalmol 1996;122:1-17.
9. Esmaeli B, Holz ER, Ahmadi MA, Krathen RA, Raad II. Endogenous endophthalmitis secondary to vancomycin-resistant enterococci infection. Retina 2003;23:118-119. (Pubitemid 36348499)
10. Sharma S, Desai RU, Pass AB, Saffra NA. Vancomycin-resistant enterococcal endophthalmitis. Arch Ophthalmol 2010;128:794-795.
11. Bains HS, Weinberg DV, Feder RS, Noskin GA. Postoperative vancomycin-resistant Enterococcus faecium endophthalmitis. Arch Ophthalmol 2007;125:1292-1293. (Pubitemid 47403045)
12. Tang CW, Cheng CK, Lee TS. Community-acquired bleb-related endophthalmitis caused by vancomycin-resistant enterococci. Can J Ophthalmol 2007;42:477-478.
13. Clark NC, Weigel LM, Patel JB, Tenover FC. Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicrob Agents Chemother 2005;49:470-472. (Pubitemid 40065837)
14. Nunes AP, Teixeira LM, Iorio NL, et al. Heterogeneous resistance to vancomycin in Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus warneri clinical strains: characterisation ofglycopeptide susceptibility profiles and cell wall thickening. Int J Antimicrob Agents 2006;27:307-315.
15. Tiwari HK, Sen MR. Emergence of vancomycin resis-tant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis 2006; 6:156.
16. Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008;46:668-674. (Pubitemid 351321548)
17. Gillis LM, White HD, Whitehurst A, Sullivan DC Vancomy-cin-tolerance among clinical isolates of Streptococcus pneu-moniae in Mississippi during 1999-2001. Am J Med Sci 2005; 330:65-68. (Pubitemid 41140461)
18. Henriques Normark B, Novak R, Ortqvist A, et al. Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin. Clin Infect Dis 2001;32:552-558. (Pubitemid 32567490)
19. Novak R, Henriques B, Charpentier E, NormarkS, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumo-niae. Nature 1999;399:590-593.
20. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) Sys-tem Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32: 470-485.
21. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007;58: 163-170. (Pubitemid 46856806)
22. Ng EW, Joo MJ, Au Eong KG, Green WR, O'Brien TP. Ocular toxicity of intravitreal trovafloxacin in the pigmented rabbit. Curr Eye Res 2003;27:387-393. (Pubitemid 38019205)
23. Pflugfelder SC, Hernandez E, Fliesler SJ, et al. Intravitreal vancomycin. Retinal toxicity, clearance, and interaction with gentamicin. Arch Ophthalmol 1987;105:831-837. (Pubitemid 17082549)
24. Zachary IG, Forster RK. Experimental intravitreal gentamicin. Am J Ophthalmol 1976;82:604-611.
25. Endophthalmitis Population Study of Western Australia (EPSWA). Management and outcomes of postoperative endophthalmitis since the Endophthalmitis Vitrectomy Study Ophthalmology 2005;112:1199-1206.
26. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. Arch Ophthalmol 1995; 113:1479-1496.
27. Brauers J, Kresken M, Menke A, et al. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococ-cus faecium using human peak free serum drug concentrations. Int J Antimicrob Agents 2007;29:322-325. (Pubitemid 46240747)
28. Pankuch GA, Jacobs MR, Appelbaum PC Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials. J Antimicrob Chemother 2003; 51:443-446. (Pubitemid 36231174)
29. Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocardi-tis and bone and joint infection. Diagn Microbiol Infect Dis 2007;58:363-365. (Pubitemid 47017650)
30. Das T, Jalali S, Gothwal VK, Sharma S, Naduvilath TJ. Intravitreal dexamethasone in exogenous bacterial endoph-thalmitis: results of a prospective randomised study. Br J Ophthalmol 1999;83:1050-1055. (Pubitemid 29433428)
31. Gan IM, Ugahary LC, van Dissel JT, et al. Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefes Arch Clin Exp Ophthalmol 2005;243:1200-1205. (Pubitemid 43055182)
32. Shah GK, Stein JD, Sharma S, et al. Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis. Ophthalmology 2000;107: 486-489. (Pubitemid 30191369)
33. Cafini F, Aguilar L, Gonzalez N, et al. In vitro effects of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. J Antimicrob Chemother 2007; 59:1185-1189. (Pubitemid 47073331)
34. Lentino JR, Strodthman R. Comparison of in vitro activity of daptomycin, vancomycin, and fluoroquinolones in broth and serum against Staphylococcus epidermidis as determined by time-killkinetics. Chemotherapy 1989;35:168-173. (Pubitemid 19161229)
35. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinu-pristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and resistant strains. Antimicrob Agents Chemother 2000;44:1062-1066. (Pubitemid 30165292)
36. Wootton M, MacGowan AP, Walsh TR. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 2006;50:4195-4197. (Pubitemid 44865169)
37. Nau R, Eiffert H. Minimizing the release of proinflammatory and toxic bacterial products within the host: a promising approach to improve outcome in life-threatening infections. FEMS Immunol Med Microbiol 2005;44:1-16. (Pubitemid 40380897)
38. Grandgirard D, Schurch C, Cottagnoud P, Leib SL. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2007;51:2173-2178. (Pubitemid 46903110)
39. Fernebro J, Andersson I, Sublett J, et al. Capsular expression in Streptococcus pneumoniae negatively affects spontaneous and antibiotic-induced lysis and contributes to antibiotic tolerance. J Infect Dis 2004;189:328-338. (Pubitemid 38147258)
40. Tuomanen E, Liu H, Hengstler B, Zak O, Tomasz A. The induction of meningeal inflammation by components of the pneumococcal cell wall. J Infect Dis 1985;151:859-868. (Pubitemid 15094604)
41. Allen NE, Alborn WE Jr, Hobbs JN Jr. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother 1991;35:2639-2642.
42. Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC. Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 2003;47:3764-3767. (Pubitemid 37484985)
43. Haworth CS, Sobieski MW, Shcheld M, Park TS. Staphylococcus aureus ventriculitis treated with a single-dose intraventricular vancomycin or daptomycin (LY146032): bacterial and antibiotic kinetics in hydrocephalic rabbits. Antimicrob Agents Chemother 1989;34:245-251. (Pubitemid 20046874)
44. Wise R, Andrews JM, Ashby JP. Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001;48:563-567. (Pubitemid 33040701)
45. Coe JI. Postmortem chemistries of human vitreous humor. Am J Clin Pathol 1969;51:741-750.
46. Naumann HN. Postmortem chemistry of the vitreous body in man. Arch Ophthalmol 1959;62:356-363.
47. Dufour DR. Lack of correlation of postmortem vitreous humor calcium concentration with antemortem serum calcium concentration. J Forensic Sci 1982;27:889-893. (Pubitemid 12003772)
48. Bito LZ. Intraocular fluid dynamics. I. Steady state concen-tration gradients of magnesium, potassium, and calcium in relation to the sites and mechanisms of ocular cation transport processes. Exp Eye Res 1970;10:102-116.
49. Lee BL, Sachdeva M, Chambers HF. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother 1991;35:2505-2508.
50. Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volun-teers. Antimicrob Agents Chemother 1992;36:318-325.